CHEMICALS · NSE/BSE: COROMANDEL

Coromandel International Limited Earnings Summary — Q4 FY2026

Sentiment: Negative
AI-generated summary
Generated 2026-06-25

Coromandel International Reports Q4 Earnings Amid Margin Contraction and Profit Dip

Net Profit
₹115 Cr
YoY -80.1%
QoQ -76.4%
Prior: ₹578 Cr
Revenue
₹6004 Cr
YoY 20.4%
QoQ -31.6%
Prior: ₹4988 Cr
Operating Margin
7%
YoY 15%
QoQ -1%
Prior: 12%
Dividend Yield
null
Full year payout ratio decreased to 17%
Net Debt / Equity
0.12
YoY 71.4%
Prior: 0.07

Key Takeaways

  • Net profit witnessed a substantial 80% year-on-year decline to ₹115 crore in Q4 FY2026.
  • Despite the profit dip, quarterly revenue grew 20% compared to the same period last year.
  • Tax expense spiked to 50% in the current quarter, significantly impacting the bottom line.
  • The company is undergoing a heavy Capex cycle, with Fixed Assets and CWIP increasing to ₹6,790 crore.
  • Borrowings have nearly doubled in the last year to ₹1,506 crore to fund expansion and working capital.
  • Other income turned negative this quarter (-₹6 Cr) versus a high base of ₹473 Cr in the previous year's Q4.
  • Depreciation costs have risen sharply to ₹165 crore as new capacities come online.

Management Guidance

Management remains focused on de-risking the business from fertilizer subsidies by expanding the Crop Protection and Biologicals segments toward a 25% profit contribution target.

Sentiment Shift

Deteriorating

A sharp decline in net profit and a spike in the tax rate and borrowing costs outweigh the moderate year-on-year revenue growth.

Deleveraging Shift
Expansionary
Agri-Cyclical

Outlook

The company is transitioning into a diversified agri-solutions provider with a focus on biologicals and exports to mitigate domestic monsoon risk; however, short-term earnings remain pressured by higher interest and depreciation.

From the Annual Report (Key Quotes)

Coromandel is India’s second-largest phosphatic fertilizer player and a dominant force in high-margin complex fertilizers.

Strategic focus on the ‘Biologicals’ business and global exports provides a structural growth tailwind.

Management is highly regarded for its corporate governance standards and strategic long-term vision.

Earnings Call Transcript — Q4 FY2026

Transcript is fetched on demand to save crawl credits. Click below to load the latest earnings call transcript for this quarter.

This summary is AI-generated from Coromandel International Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.

← Back to Coromandel International Limited AI analysis